The development of genotyping technologies has allowed for wider screening for inherited causes of variable outcomes following drug administration. We have performed a genome-wide association study (GWAS) on 221 colorectal cancer (CRC) patients that had been treated with 5-fluorouracil (5-FU), either alone or in combination with oxaliplatin (FOLFOX). A validation set of 791 patients was also studied. Seven SNPs (rs16857540, rs2465403, rs10876844, rs10784749, rs17626122, rs7325568 and rs4243761) showed eviIntroduction It has been known for many decades, that there is an important inter-individual variation in an individual's response to drug administration. 1 This variation may be represented, for instance, by differences in the delivery of the drug molecule, or by factors that affect drug targeting. This divergence usually results in either the lack of the desired therapeutic effect, or the occurrence of adverse drug reactions (ADRs), with several factors, such as age, sex, intake of other drugs and inheritance, influencing this outcome. 2 Colorectal cancer (CRC) is the third most frequent form of neoplasm, and an important cause of morbidity in the developed world. 3 There has been increasing evidence from clinical trials that chemotherapy treatment greatly improves the chances of healing and survival in CRC patients with stages III or higher. 5-FU has been the cornerstone for first-line CRC systematic chemotherapy for many years, 4, 5 and its combination with oxaliplatin (that is, FOLFOX) has become the most common regimen for CRC patients. 6 However, the toxicities associated with the administration of these drugs have sometimes overshadowed the benefits they deliver. Patients treated with 5-FU commonly exhibit gastrointestinal and haematopoietic toxicities, whereas FOL-FOX-treated patients are at risk of developing sensory neuropathy, which may endure even long after cessation of chemotherapy. 7 All these side effects are thought to be mainly due to the narrow therapeutic indexes of most anticancer drugs.
Until recently, the investigation of the inheritance factors underlying the diverse response to CRC chemotherapy agents had mainly focused on candidate-gene studies, in which variants in genes coding for proteins involved in specific pathways, such as drug absorption, metabolism or target molecules, were screened for evidence of their association with therapy outcome. For instance, variants in candidate genes such as DPYD, 8 TYMS 9 or UGT1A1 10 have already been linked to the development of ADRs in CRC patients treated with chemotherapy. However, these relatively rare and large-effect phenotypes might not apply to the majority of drugs or patients. It is expected that for common pharmacogenetic traits, as for most diseases, the inheritance patterns behind these responses are complex, with an interplay of multiple variants in the determination of the final outcome. 11 In this sense, candidate-gene association studies have been proven to be an important tool for the identification of some of these other variants. 12, 13 However, the simultaneous study of higher numbers of variants has become increasingly necessary in order to evaluate the full contribution of inheritance to drug response. Genome-wide association study (GWAS) may therefore be an important tool for this purpose. The main advantage of this type of study in opposition to gene-based strategies is that they may be able to identify variants in genes or pathways that have not been implicated in mediating drug response so far.
14 Nonetheless, there have still been no reports of GWAS in relation to CRC chemotherapy, neither for drug response, nor for ADRs. The discovery of the genetic factors underlying this expected heritability may be fundamental for the adjustment of therapies and/or dosage in order to achieve a better outcome.
Thus, we decided to perform an unprecedented GWAS on a cohort of samples that had either been treated with 5-FU or FOLFOX with the aim to shed a light on the genetic variation behind a series of gastrointestinal (diarrhoea, mucositis, nausea/vomiting), haematological (anaemia, neutropenia, leukopenia, thrombocytopenia), and neurological (oxaliplatin-related neuropathy) ADRs.
Materials and methods

Study populations
Samples from GWAS phase I consisted of 221 CRC patients collected through the EPICOLON II project, 15 a multicentre study of the prevalence and clinic-pathological features of CRC in the Spanish population. Colon cancer patients had received adjuvant or palliative 5-FU or FOLFOX-based chemotherapy, whereas rectal cancer patients had undergone 5-FU or FOLFOX-based chemotherapy or a combination of these regimens with radiation therapy. CRC patients receiving other chemotherapeutical schedules were excluded from the study. Clinical and toxicity-related information was obtained from each of these individuals using a pre-established, standardized form.
Samples from phase II represented 791 CRC patients collected at four different centers. Samples from Hospital Sant Pau (Barcelona) were 118 patients diagnosed with CRC and receiving either of the treatments. 16 Samples from the Catalan Institute of Oncology (ICO, Barcelona, n ¼ 432) belonged to the Bellvitge Colorectal Cancer Study, and were hospital-based patients with a new diagnosis of CRC. Samples from Hospital Gregorio Marañó n (Madrid, n ¼ 104) were obtained from diagnosed CRC patients, who had agreed to participate in a pharmacogenetic survey of efficacy and toxicity to 5-FU and FOLFOX. Samples from the Complexo Hospitalario Universitario de Santiago (n ¼ 144), are a subsample of all participants included in a pharmacogenetic study.
All samples were from individuals of Caucasian European origin and from Spain. DNA was obtained from peripheral blood by standard extraction methods. Clinical and populational features for cohorts at both stages are shown on Table 1 .
Ethics statement
The study was approved by both the institutional review boards of the hospitals where samples were collected and the 'Comité É tico de Investigació n Clínica de Galicia'. All samples were obtained with written informed consent reviewed by the ethical board of the corresponding hospital, in accordance with the Declaration of Helsinki.
Adverse effects and phenotype coding Toxicity responses for seven different adverse reactions were recorded for each patient during their chemotherapy . A delay was considered to have happened if this deviation was X2 or 3 weeks for cycle numbers below or over 6, respectively). Secondly, we also acknowledged the reductions in chemotherapeutical agent as registered in the filled toxicity forms. Given this, we considered grade-1 toxicity individuals as cases whenever: a) the number of chemotherapy cycles received was p4 for either 5-FU or FOLFOX; b) the number of cycles was 44 but the sample had suffered dosage reduction and/or had been qualified as 'delayed' according to the above-mentioned criteria. If neither of these conditions was fulfilled, grade-1 toxicity individuals were regarded to as controls. All other toxicity grades were considered as cases, regardless of the circumstances. A simplification of the classification algorithm is shown on Supplementary Figure 1 . This procedure was repeated for every one of the five phenotypes. Inclusion of a sample in the case group for one of the phenotypes did not exclude the possibility that the same sample could also be a case for other ADR. On the other hand, due to the low numbers of cases for some of the ADRs (that is neutropenia and thrombocytopenia) and the fact that all of the cell types involved derive the same stem cell type, we decided to consider these two side effects, along with anaemia and leukopenia, as a single variable (haematological adverse effects). Similar groupings have already been described elsewhere in the literature. 17, 18 SNP genotyping and quality control The Affymetrix SNP 6.0. array (Affymetrix, Santa Clara, CA, USA) was used for the screening of variants related to toxicity responses in colorectal cancer patients treated with 5-FU and FOLFOX in phase I of the study. For phase II genotyping, Sequenom MassARRAY (Sequenom, San Diego, CA, USA) was used. Genotype calling from array intensities on phase I was achieved with the use of the Birdseed algorithm, included in Birdsuite v1. 4 . 19 Conversion of the data into PLINK v1.07 20 format utilised in-house scripts. By these means, we obtained an initial set of 909 622 SNPs. The minor allele frequency (MAF) filtering threshold was set to X0.15 in order to avoid noise derived from the low sample size numbers. Genotyping success inclusion criteria, both for samples and markers, were set at 95%, and individuals were also checked for concordance of genders between clinical data and the Affymetrix-assigned sex. Hardy-Weinberg Equilibrium was also tested, and markers with P-values o0.001 were removed from subsequent analyses. Differential missingness in cases vs controls was assessed for each phenotypic group, although no additional markers were removed because of this criterion. Principal component analysis on 55 000 independent SNP markers, with the aim of detecting any underlying population stratification, was performed with the EIGENSOFT smartpca tool. 21 HLA (chr6:25.5-33.5 Mb; 57-64 Mb; 140-142.5 Mb) and longrange linkage disequilibrium regions 22 were excluded from the analysis. No significant differences were observed between case and control groups for either the 5-FU nor the FOLFOX groups or any of the ADR phenotypes for the first 10 eigenvectors. No differences were found regarding the hospital of origin of the samples either (principal component analysis data not shown). The Quantile-Quantile plots comparing the expected and observed association P-values (Supplementary Figure 2) were performed in R. 23 Genomic Control values ranged from 0.889 to 1.025 for 5-FU and 1.003 to 1.034 FOLFOX. After these filtering procedures, 497 366 SNPs in 88 individuals, and 497 913 SNPs in 115 individuals remained for the 5-FU and FOLFOX treatments, respectively. The great drop in markers corresponds mainly to the MAF restrictions. The total number of case/control counts for each phenotype and phase is shown in Table 2 .
We also evaluated associations that had previously been linked to ADRs after 5-FU and FOLFOX treatments by means of an overview on already published SNPs or their closest proxies on our array. The selection of the markers was performed with the help of the PharmGKB database (http:// www.pharmgkb.org/), and was restricted to only those variants with MAF45%: rs1801159, rs1801265, rs1801019, rs1801133, rs34743033, rs34489327 and rs1695.
Statistical analysis SNP association analyses were performed by logistic regression in PLINK. 18 Covariate adjustment was also used to correct for gender and severity of the toxicities (grades 1-2 vs 3-4) during the testing. Hospital of origin of the sample was also adjusted for in phase II analyses. ORs (Odds ratios) and 95% confidence intervals were calculated for each marker. Additional plots were created using Haploview 24 and R. Copy-number variations (CNV) calling and analysis Both CNV and SNP probes on the array were used to screen for structural variation and CNV characterisation. Copynumber status was estimated by two different methods: the Birdseye algorithm, another part of Birdsuite's framework, 19 and QuantiSNP version 2, 25 which includes a modification that implements the use of the CN-probe information on Affymetrix arrays. Once the calling was made, CNVs were filtered according to their MAFs (45%) and the probability Pharmacogenomics of 5-FU and FOLFOX in CRC C Fernandez-Rozadilla et al score associated with each calling algorithm. Quality control thresholds were set at LOD-scores 410 for Birdseye CNVs and a Bayes Factor 430 for QuantiSNP results. Association analyses were then performed with the help of CNVAssoc, an in-house tool that allows for the comparison of CNV event frequencies among cases and controls. Briefly, it considers the presence of a number of different copynumber states: homozygous deletion (0), single deletion (1), three, four or five copies (3, 4, 5) , any loss (0 þ 1), any gain (3 þ 4 þ 5) and any CNV (0 þ 1 þ 3 þ 4 þ 5). Then, for each, it counts the incidence of every one of these copynumber states against the absence of the same, creating two-by-two contingency tables (that is, copy-number 3 vs no-copy-number 3) that can be used to calculate Fisher's exact test for association. It also implements a copy-number polymorphism test approach, in which each CNV is considered to behave as a common variant. By these means, the inheritance of such variation should follow a three-state Mendelian pattern and the alleles should be in Hardy-Weinberg equilibrium. If the counts do not fit this equilibrium (P threshold 10E-06), then the change may as well be unstable, multiallelic or a rare CNV.
CNV genotyping is somewhat more complicated than that for SNPs. Therefore, for replication purposes, tag SNPs were selected at each of the associated CNV regions, according to the data made available by the Wellcome Trust Case Control Consortium. 26 Only CNVs with described SNP tags at r 2 40.8 were considered. This strategy was used as a means of replication of the CNV association signals found in phase I. These were genotyped and analysed in the same way as described for the phase II SNP markers (with the exception of pooled analyses).
Results
The results for the phase I SNP analysis on 88 patients receiving 5-FU and 115 patients treated with FOLFOX are shown in Figure 1 . Association P-values were very modest (best P ¼ 1.076E-05), with none reaching the established genome-wide significance level at 10E-07. We then genotyped in a second phase the top 5 association hits (by P-value) for each of the treatment-phenotype pairs, with the exception of neuropathy, for which the top 10 loci were Figure 3) . Association P-value results for the 'any CNV' test were lowest for regions at 2p22.3 (5-FU-nausea/vomiting), 11p11.12 and 20p13 (5-FUhaematologic) and 11p15.4 (FOLFOX-diarrhoea). Another 
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C Fernandez-Rozadilla et al CNV at 5q35.3 seemed to share susceptibility to 5-FUinduced haematological effects and FOLFOX-related mucositis ( Table 4 ). All of these were documented copy-number variation sites and were well tagged by nearby SNPs. 26 There were some CNV regions that showed similar P-values but were not well tagged by SNP markers, and thus could not be replicated by means of our indirect approach.
Replication values of the top 50 hits for SNPs and the 5 CNV-associated SNP taggers from phase I and pooled analysis of both phases may be seen in Table 5 . Only one of these association signals was consistent in both phases: rs10876844 at 12q13.2 with diarrhoea in patients treated with 5-FU (pooled P ¼ 0.010; OR ¼ 6.502 (1.552-27.230)). Linkage disequilibrium blocks around this region are shown in Supplementary Figure 4 . Nevertheless, there were another six SNPs that, although not significant in the replication phase, did show significant association values in the pooled analysis of the two phases, although not at GWAS levels. These were rs16857540, rs2465403, rs10784749, rs17626122, rs7325568 and rs4243761 (Table 5) .
We also evaluated the association signals for seven SNP variants that had been linked to either 5-FU or FOLFOXrelated toxicity in the literature. Four of these variants had good proxy SNPs in our GWAS, although none of them showed a statistically significant association (Table 6 ).
Discussion
Although candidate-gene strategies have provided with some clues to the genetics underlying drug responses and toxicity outcomes, 12, 13 there has been an increasing interest in GWAS studies in pharmacogenetics in the last years. 30 As major toxicity remains the main limitation to adequate dosing in chemotherapy treatments, the ability to predict toxicity before drug administration could help to provide individualised treatment that would likely result in an improved outcome, both for the sake of the patient and pharmacoeconomic purposes. In this work, we present the results of the first GWAS study of the toxicity outcome of 5-FU and FOLFOX administration in colorectal cancer patients. We have successfully identified seven new variants related to 5-FU-induced and FOLFOXrelated side effects. Even when copy-number alterations account for a high percentage of the total variation in the genome, 32 we did not succeed in identifying any signals of association regarding CNVs and the ADRs in our study.
The only consistent association signal throughout both phases was that of rs10876844 with diarrhoea in patients treated with 5-FU. This SNP lies in the long arm of chromosome 12, 24 and 26 kb upstream of the METTL7B (methyl-transferase like 7B precursor) and ITGA7 (integrin alpha 7 isoform 1 precursor) genes, respectively. Although analysis of the linkage disequilibrium pattern in this region seemed to show that rs10876844 and the gene blocks were not well correlated, this however does not rule out the possibility that rs10876844 may be capturing part of the known, or even yet unknown variation in any of these genes. Nevertheless, the presence of this variant in an intergenic region makes it difficult to directly understand its functional outcome. Therefore, further functional studies will be needed to clarify how it affects diarrhoea susceptibility in 5-FU-treated patients.
Even when phase II association values were not significant, there were some other six SNPs that held significance in the pooled analysis of the two phases. It has been suggested that joint analysis of phases may be more powerful in detecting true association signals than phase-based designs particularly in studies with low sample sizes. 33 This may be so because the pooling analysis allows for an improvement in power in the overall study compared with each of the phases independently. Thus, we consider these six variants as interesting locations and do not fully discard them as potential susceptibility loci for adverse reactions after 5-FU and FOLFOX administration.
Of these other six SNPs, rs16857540, rs2465403 and rs17626122 fall within the intronic regions of the NLGN1, COLEC10 and PARD3B genes. The remaining three, rs10784749, rs7325568 and rs4243761, lie however in intergenic locations. Although a possible connection between the NLGN1 and the COLEC10 genes and mucositis does not seem very clear, the PARD3B protein has been shown to interact with SMAD3, one of the members of the TGF-signalling pathway. Mutations in SMAD3 have already been linked to colorectal adenocarcinoma development in mice 34 and wound healing. 35 Furthermore, we did not succeed in replicating any of the association signals described at other loci in previous literature.
9,27-29 It must however be noted that these negative findings could result from the fact that the variants were not directly genotyped in our samples, with r 2 values for the proxy markers being sometimes small (below 0.8). Hence, we would recommend these to be additionally evaluated in other cohorts in order to fully assess their relationship with ADR susceptibility.
Although CNVs have been proposed as a potential source of genetic variability, and might greatly influence pharmacogenetic outcome, we could not replicate the association signals in any of the CNVs selected for our second phase replication. However, we must take into consideration the fact that some CNVs showing similar P-values could not be replicated because of the lack of a suitable SNP tagger. Therefore, investigations on the relationship between these loci and ADR presence must be undertaken by other methodologies, such as qPCR or MLPA.
We must also bear in mind that, for some of these markers (particularly for 5-FU SNPs rs2465403 and rs10876844), OR ranges were exceptionally wide, thus possibly reflecting a type-I error or the inability of the study to precisely estimate the risk associated with that variant due to sample size restrictions. Scientists have largely speculated on the idea that the variants contributing to pharmacogenetic traits have escaped the effects of human selection, thus resulting in effect sizes higher than those discovered for GWAS of disease susceptibility. 36 Even when the predicted ORs for the associated variants are somewhat higher than those obtained for the majority of the GWAS and susceptibility to disease signals, the prediction of the effects of these variants is moderate. This observation would effectively result in a Markers were selected from previous bibliography whenever described MAFs were o5%.
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C Fernandez-Rozadilla et al reduction in power, given the low sample sizes for some of the phenotypes (particularly in phase I). Although measures have been taken to minimise this power decrease (for instance by restricting the MAF of the markers studied) and improve result consistency (by a second phase replication), it is probable that many lower effect susceptibility variants have been missed. This would reinforce both the need for further follow-up studies in larger cohorts in order to fully ascertain the relationship between these variants and ADR susceptibility, as well as the use of GWAS screenings as an ideal strategy for the identification of new variants.
Of course, GWAS also show some considerable limitations. In opposition to candidate-gene strategies, the interpretation of the results, in terms of description of the underlying processes, is not often straightforward, and the real biological mechanisms underlying these associations are still unknown. This however, does not rule out the relevance of the discoveries and we encourage further efforts be made in this direction. The verification of the association signals reported in this study with their presumptive ADRs would ultimately need to be ascertained by replication in larger data sets. Fine-mapping studies and subsequent functional assays will eventually also be required in order to clarify the biological mechanisms underlying these association signals.
